What should I avoid while taking Amiloride 500micrograms/5ml oral solution?

Avoid drastic dietary changes. Avoid natural licorice. Avoid potassium-containing products. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Amiloride 500micrograms/5ml oral solution?

Amiloride 500micrograms/5ml oral solution is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Amiloride 500micrograms/5ml oral solution?

Amiloride 500micrograms/5ml oral solution is the generic name. It is available under brand names including: Amiloride 500micrograms/5ml oral solution. (Source: NHS dm+d — Actual Medicinal Products)

Amiloride 500micrograms/5ml oral solution

Prescription only

Requires a prescription from a doctor or prescriber

Oral solution

5ml

Oral

Antihypertensive

A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells.

Active ingredients:

Amiloride

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.02.03

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C03DB01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antihypertensive

Check interactions for Amiloride

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Amiloride

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Amiloride

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Amiloride

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Amiloride on the MHRA register

Amiloride 500micrograms/5ml oral solution

Special Order

None

Special

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

10 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Amiloride 1.5mg/5ml oral suspension

Oral suspension

1.5mg/5ml

Same therapeutic group

Amiloride 1.5mg/5ml oral solution

Oral solution

1.5mg/5ml

Same therapeutic group

Amiloride 1.7mg/5ml oral suspension

Oral suspension

1.7mg/5ml

Same therapeutic group

Amiloride 1.7mg/5ml oral solution

Oral solution

1.7mg/5ml

Same therapeutic group

Amiloride 12.5mg/5ml oral suspension

Oral suspension

12.5mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Amiloride

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Amiloride

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

8273911000001103

dm+d ID

8273911000001103

VTM (Virtual Therapeutic Moiety)

774535004

VMP (Virtual Medicinal Product)

8273911000001103

BNF code

02020300

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C03DB01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

12 found

Half-life

6 to 9 hours

Mechanism

Amiloride works by inhibiting sodium reabsorption in the distal convoluted tubul…

Food interactions

4 warnings

Human targets

9 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Readily absorbed following oral administration.

Half-life

6 to 9 hours

Plasma half-life varies from 6 to 9 hours.

Metabolism

Amiloride is not metabolized by the liver but is excreted unchanged by the kidneys.

Elimination

20 mg

Amiloride HCl is not metabolized by the liver but is excreted unchanged by the kidneys.…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)

Properties:

solid

Avg. mass: 229.63 Da

View FDA drug label

DrugBank indication

For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.

Also known as(113)

3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide

Amilorid

Amilorida

Amiloride

Amiloridum

Amipramidin

Amipramidine

Amyloride

Dosage forms(8)

Tablet (Oral)

Tablet (Oral) — 5 mg/1

Tablet (Oral)

Tablet (Oral) — 5 mg

Tablet, film coated (Oral)

Tablet (Oral) — 5.0 mg

Tablet (Oral) — 5 mg

Tablet (Oral) — 50.000 mg

Molecular properties(19)

Drug interactions(1077)

Known interactions with other medications. Always consult a healthcare professional.

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Amiloride is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Amiloride is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Amiloride may increase the hypotensive activities of Risperidone.

Check this interaction

Dofetilide

Moderate

DB00204

Amiloride may decrease the excretion rate of Dofetilide which could result in a higher serum level.

Check this interaction

Aripiprazole

Moderate

DB01238

Aripiprazole may increase the hypotensive activities of Amiloride.

Check this interaction

Aripiprazole lauroxil

Moderate

DB14185

Aripiprazole lauroxil may increase the hypotensive activities of Amiloride.

Check this interaction

Nicorandil

Moderate

DB09220

Nicorandil may increase the hypotensive activities of Amiloride.

Check this interaction

Digoxin

Moderate

DB00390

Amiloride may decrease the excretion rate of Digoxin which could result in a higher serum level.

Check this interaction

Acetyldigitoxin

Moderate

DB00511

Amiloride may decrease the excretion rate of Acetyldigitoxin which could result in a higher serum level.

Check this interaction

Deslanoside

Moderate

DB01078

Amiloride may decrease the excretion rate of Deslanoside which could result in a higher serum level.

Check this interaction

Ouabain

Moderate

DB01092

Amiloride may decrease the excretion rate of Ouabain which could result in a higher serum level.

Check this interaction

Digitoxin

Moderate

DB01396

Amiloride may decrease the excretion rate of Digitoxin which could result in a higher serum level.

Check this interaction

Oleandrin

Moderate

DB12843

Amiloride may decrease the excretion rate of Oleandrin which could result in a higher serum level.

Check this interaction

Cymarin

Moderate

DB13240

Amiloride may decrease the excretion rate of Cymarin which could result in a higher serum level.

Check this interaction

Proscillaridin

Moderate

DB13307

Amiloride may decrease the excretion rate of Proscillaridin which could result in a higher serum level.

Check this interaction

Metildigoxin

Moderate

DB13401

Amiloride may decrease the excretion rate of Metildigoxin which could result in a higher serum level.

Check this interaction

Lanatoside C

Moderate

DB13467

Amiloride may decrease the excretion rate of Lanatoside C which could result in a higher serum level.

Check this interaction

Gitoformate

Moderate

DB13537

Amiloride may decrease the excretion rate of Gitoformate which could result in a higher serum level.

Check this interaction

Acetyldigoxin

Moderate

DB13691

Amiloride may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.

Check this interaction

Peruvoside

Moderate

DB13756

Amiloride may decrease the excretion rate of Peruvoside which could result in a higher serum level.

Check this interaction

Cyclosporine

Unknown severity

DB00091

The risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclosporine.

Check this interaction

Icosapent

Unknown severity

DB00159

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Icosapent is combined with Amiloride.

Check this interaction

Mesalazine

Unknown severity

DB00244

The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Amiloride.

Check this interaction

Nabumetone

Unknown severity

DB00461

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Amiloride.

Check this interaction

Ketorolac

Unknown severity

DB00465

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Amiloride.

Check this interaction

Tenoxicam

Unknown severity

DB00469

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Amiloride.

Check this interaction

Celecoxib

Unknown severity

DB00482

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Amiloride.

Check this interaction

Tolmetin

Unknown severity

DB00500

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Amiloride.

Check this interaction

Rofecoxib

Unknown severity

DB00533

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Amiloride.

Check this interaction

Piroxicam

Unknown severity

DB00554

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Amiloride.

Check this interaction

Fenoprofen

Unknown severity

DB00573

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Amiloride.

Check this interaction

Valdecoxib

Unknown severity

DB00580

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Amiloride.

Check this interaction

Diclofenac

Unknown severity

DB00586

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Amiloride.

Check this interaction

Sulindac

Unknown severity

DB00605

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Amiloride.

Check this interaction

Flurbiprofen

Unknown severity

DB00712

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen is combined with Amiloride.

Check this interaction

Etodolac

Unknown severity

DB00749

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etodolac is combined with Amiloride.

Check this interaction

Mefenamic acid

Unknown severity

DB00784

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Amiloride.

Check this interaction

Naproxen

Unknown severity

DB00788

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Amiloride.

Check this interaction

Sulfasalazine

Unknown severity

DB00795

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Amiloride.

Check this interaction

Phenylbutazone

Unknown severity

DB00812

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Amiloride.

Check this interaction

Carprofen

Unknown severity

DB00821

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carprofen is combined with Amiloride.

Check this interaction

Diflunisal

Unknown severity

DB00861

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diflunisal is combined with Amiloride.

Check this interaction

Salicylic acid

Unknown severity

DB00936

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Amiloride.

Check this interaction

Meclofenamic acid

Unknown severity

DB00939

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Amiloride.

Check this interaction

Oxaprozin

Unknown severity

DB00991

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxaprozin is combined with Amiloride.

Check this interaction

Ketoprofen

Unknown severity

DB01009

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Amiloride.

Check this interaction

Balsalazide

Unknown severity

DB01014

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Amiloride.

Check this interaction

Ibuprofen

Unknown severity

DB01050

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Amiloride.

Check this interaction

Lumiracoxib

Unknown severity

DB01283

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lumiracoxib is combined with Amiloride.

Check this interaction

Magnesium salicylate

Unknown severity

DB01397

The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Amiloride.

Check this interaction

Showing 50 of 1077 interactions

Food & lifestyle interactions

Advice

Avoid drastic dietary changes.

Advice

Avoid natural licorice.

Advice

Avoid potassium-containing products.

Take With Food

Take with food. Food reduces irritation.

Toxicity & overdose

No data are available in regard to overdosage in humans. The oral LD₅₀ of amiloride hydrochloride (calculated as the base) is 56 mg/kg in mice and 36 to 85 mg/kg in rats, depending on the strain. The most likely signs and symptoms to be expected with overdosage are dehydration and electrolyte imbalance.

How it works

Mechanism of action

Amiloride works by inhibiting sodium reabsorption in the distal convoluted tubules and collecting ducts in the kidneys by binding to the amiloride-sensitive sodium channels. This promotes the loss of sodium and water from the body, but without depleting potassium. Amiloride exerts its potassium sparing effect through the inhibition of sodium reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct; this decreases the net negative potential of the tubular lumen and reduces both potassium and hydrogen secretion and their subsequent excretion. Amiloride is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone.

Pharmacodynamics

Amiloride, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is an antihypertensive, potassium-sparing diuretic that was first approved for use in 1967 and helps to treat hypertension and congestive heart failure. The drug is often used in conjunction with thiazide or loop diuretics. Due to its potassium-sparing capacities, hyperkalemia (high blood potassium levels) are occasionally observed in patients taking amiloride. The risk is high in concurrent use of ACE inhibitors or spironolactone. Patients are also advised not to use potassium-containing salt replacements.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Readily absorbed following oral administration.

Half-life

Plasma half-life varies from 6 to 9 hours.

Metabolism

Amiloride is not metabolized by the liver but is excreted unchanged by the kidneys.

Route of elimination

Amiloride HCl is not metabolized by the liver but is excreted unchanged by the kidneys. About 50 percent of a 20 mg dose of amiloride HCl is excreted in the urine and 40 percent in the stool within 72 hours.

Drug targets(9)

Proteins and enzymes this drug interacts with in the body

Epithelial sodium channel subunit alpha

BE0000190

SCNN1A

inhibitor

Specific functionligand-gated sodium channel activity

Cellular location

Apical cell membrane

General function & pharmacology

This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis .
PMID:30251954 PMID:32729833 PMID:8023962 PMID:8278374 PMID:9792722

ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically .
PMID:24124190 PMID:28710092 PMID:8278374

It plays a key role in maintaining sodium homeostasis through electrogenic sodium reabsorption in the kidneys .
PMID:12107247
Additionally, ENaC is essential for airway surface liquid homeostasis, which is crucial for proper mucus clearance PMID:24124190 PMID:28710092

Epithelial sodium channel subunit beta

BE0000024

SCNN1B

inhibitor

Specific functionligand-gated sodium channel activity

Cellular location

Apical cell membrane

General function & pharmacology

This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis .
PMID:30251954 PMID:32729833 PMID:7762608 PMID:9792722

ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically .
PMID:24124190
It plays a key role in maintaining sodium homeostasis through electrogenic sodium reabsorption in the kidneys .
PMID:12107247
Additionally, ENaC is essential for airway surface liquid homeostasis, which is crucial for proper mucus clearance PMID:24124190

Epithelial sodium channel subunit gamma

BE0000497

SCNN1G

inhibitor

Specific functionligand-gated sodium channel activity

Cellular location

Apical cell membrane

General function & pharmacology

This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis .
PMID:30251954 PMID:32729833 PMID:7550319 PMID:7762608 PMID:9792722

ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically .
PMID:24124190
It plays a key role in maintaining sodium homeostasis through electrogenic sodium reabsorption in the kidneys .
PMID:12107247 PMID:7550319 PMID:8640238

Additionally, ENaC is essential for airway surface liquid homeostasis, which is crucial for proper mucus clearance PMID:18507830 PMID:19017867 PMID:24124190

Epithelial sodium channel subunit delta

BE0000495

SCNN1D

inhibitor

Specific functionligand-gated sodium channel activity

Cellular location

Apical cell membrane

General function & pharmacology

Potential alternative pore-forming subunit of the epithelial sodium channel (ENaC), capable of replacing the alpha/SCNN1A subunit, creating a more active channel with distinct properties .
PMID:16423824 PMID:19520916 PMID:22505667

ENaC functions in epithelial tissues, where it facilitates the electrodiffusion of sodium ions from the extracellular fluid through the apical membrane of cells, with water following osmotically, regulating sodium balance and fluid homeostasis .
PMID:16423824 PMID:19520916 PMID:7499195

This subunit could also function independently as a sodium channel or assemble into other tissue-specific heterotrimeric sodium channels PMID:7499195

Diamine oxidase [copper-containing]

BE0000351

AOC1

inhibitor

Specific functioncalcium ion binding

Cellular location

Secreted, extracellular space

General function & pharmacology

Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia .
PMID:12072962 PMID:19764817 PMID:239684 PMID:8144586

Its preferred substrates are the diamines histamine and 1-methylhistamine and it could therefore play a role in allergic and immune responses .
PMID:12072962
Has a broad specificity for diamines and can also act on cadaverine and putrescine, two products of amino acid catabolism .
PMID:12072962
It could also act on polyamines, like spermidine and spermine though less efficiently, and regulate various biological processes PMID:12072962 PMID:239684

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

AOC1Diamine oxidase [copper-containing]

inhibitor

Transporters(2)

Proteins that transport this drug across cell membranes

Solute carrier family 22 member 2

BE0003647

SLC22A2

inhibitor

Specific functionacetylcholine transmembrane transporter activity

Cellular location

Basolateral cell membrane

General function & pharmacology

Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics .
PMID:9260930 PMID:9687576
Functions as a Na(+)-independent, bidirectional uniporter .
PMID:21128598 PMID:9687576
Cation cellular uptake or release is driven by the electrochemical potential, i.e. membrane potential and concentration gradient .
PMID:15212162 PMID:9260930 PMID:9687576

However, may also engage electroneutral cation exchange when saturating concentrations of cation substrates are reached (By similarity). Predominantly expressed at the basolateral membrane of hepatocytes and proximal tubules and involved in the uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow .
PMID:15783073
Implicated in monoamine neurotransmitters uptake such as histamine, dopamine, adrenaline/epinephrine, noradrenaline/norepinephrine, serotonin and tyramine, thereby supporting a physiological role in the central nervous system by regulating interstitial concentrations of neurotransmitters .
PMID:16581093 PMID:17460754 PMID:9687576

Also capable of transporting dopaminergic neuromodulators cyclo(his-pro), salsolinol and N-methyl-salsolinol, thereby involved in the maintenance of dopaminergic cell integrity in the central nervous system .
PMID:17460754
Mediates the bidirectional transport of acetylcholine (ACh) at the apical membrane of ciliated cell in airway epithelium, thereby playing a role in luminal release of ACh from bronchial epithelium .
PMID:15817714
Also transports guanidine and endogenous monoamines such as vitamin B1/thiamine, creatinine and N-1-methylnicotinamide (NMN) .
PMID:12089365 PMID:15212162 PMID:17072098 PMID:24961373 PMID:9260930

Mediates the uptake and efflux of quaternary ammonium compound choline .
PMID:9260930
Mediates the bidirectional transport of polyamine agmatine and the uptake of polyamines putrescine and spermidine .
PMID:12538837 PMID:21128598
Able to transport non-amine endogenous compounds such as prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) .
PMID:11907186
Also involved in the uptake of xenobiotic 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP) .
PMID:12395288 PMID:16394027
May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)

Solute carrier family 22 member 4

BE0000757

SLC22A4

inhibitor

Specific functionacetylcholine transmembrane transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Transporter that mediates the transport of endogenous and microbial zwitterions and organic cations .
PMID:10215651 PMID:15107849 PMID:15795384 PMID:16729965 PMID:20601551 PMID:22206629 PMID:22569296 PMID:29530864

Functions as a Na(+)-dependent and pH-dependent high affinity microbial symporter of potent food-derived antioxidant ergothioeine .
PMID:15795384 PMID:29530864 PMID:33124720

Transports one sodium ion with one ergothioeine molecule (By similarity). Involved in the absorption of ergothioneine from the luminal/apical side of the small intestine and renal tubular cells, and into non-parenchymal liver cells, thereby contributing to maintain steady-state ergothioneine level in the body .
PMID:20601551
Also mediates the bidirectional transport of acetycholine, although the exact transport mechanism has not been fully identified yet .
PMID:22206629
Most likely exports anti-inflammatory acetylcholine in non-neuronal tissues, thereby contributing to the non-neuronal cholinergic system .
PMID:22206629 PMID:22569296
Displays a general physiological role linked to better survival by controlling inflammation and oxidative stress, which may be related to ergothioneine and acetycholine transports .
PMID:15795384 PMID:22206629
May also function as a low-affinity Na(+)-dependent transporter of L-carnitine through the mitochondrial membrane, thereby maintaining intracellular carnitine homeostasis .
PMID:10215651 PMID:15107849 PMID:16729965

May contribute to regulate the transport of cationic compounds in testis across the blood-testis-barrier PMID:35307651

Biological pathways(1)

Amiloride Action Pathway

Involved compounds

Amiloride,Cysteine,Potassium cation,Urea

ATC classification(1 code)

ATC C03DB01

Affected organisms(1)

Humans and other mammals

International brands(4)

Salt forms(2)

Amiloride hydrochloride(DBSALT001807)

Amiloride hydrochloride dihydrate(DBSALT000270)

Experimental properties(4)

External resources(3)

RxList PDRhealth Drugs.com

Protein Data Bank entries(2)

1f5l

4ntx

Commercial products(35)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Amiloride

DB00594

CAS number

2609-46-3

UNII (FDA)

7DZO8EB0Z3

InChI Key (molecular fingerprint)

XSDQTOBWRPYKKA-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

20230

ChEBI

2639

PubChem Compound

16231

PubChem Substance

46508156

KEGG Compound

C06821

KEGG Drug

D07447

ChemSpider

15403

BindingDB

16173

PharmGKB

PA448368

PDB

AMR

Therapeutic Targets Database

DAP000187

IUPHAR

2421

Guide to Pharmacology

2421

Wikipedia

Amiloride

ChEMBL

CHEMBL945

ZINC

ZINC000004340269

RxCUI

644

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10599

GenAtlas

SCNN1A

GeneCards

SCNN1A

GenBank Gene Database

X76180

GenBank Protein Database

452650

Guide to Pharmacology

738

UniProtKB

P37088

UniProt Accession

SCNNA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10600

GenAtlas

SCNN1B

GeneCards

SCNN1B

GenBank Gene Database

X87159

GenBank Protein Database

1004271

Guide to Pharmacology

739

UniProtKB

P51168

UniProt Accession

SCNNB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10602

GenAtlas

SCNN1G

GeneCards

SCNN1G

GenBank Gene Database

X87160

GenBank Protein Database

1004273

Guide to Pharmacology

741

UniProtKB

P51170

UniProt Accession

SCNNG_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10601

GenAtlas

SCNN1D

GeneCards

SCNN1D

GenBank Gene Database

U38254

GenBank Protein Database

1066457

UniProtKB

P51172

UniProt Accession

SCNND_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:80

GenAtlas

ABP1

GeneCards

AOC1

GenBank Gene Database

M55602

GenBank Protein Database

177960

UniProtKB

P19801

UniProt Accession

AOC1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:99

GenAtlas

ACCN1

GeneCards

ASIC2

GenBank Gene Database

U50352

GenBank Protein Database

1256017

Guide to Pharmacology

685

UniProtKB

Q16515

UniProt Accession

ASIC2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:100

GenAtlas

ACCN2

GeneCards

ASIC1

GenBank Gene Database

U78180

GenBank Protein Database

1871168

Guide to Pharmacology

684

UniProtKB

P78348

UniProt Accession

ASIC1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11071

GenAtlas

SLC9A1

GeneCards

SLC9A1

GenBank Gene Database

M81768

GenBank Protein Database

178753

UniProtKB

P19634

UniProt Accession

SL9A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:9052

GenAtlas

PLAU

GeneCards

PLAU

GenBank Gene Database

X02419

GenBank Protein Database

1834524

Guide to Pharmacology

2393

UniProtKB

P00749

UniProt Accession

UROK_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:80

GenAtlas

ABP1

GeneCards

AOC1

GenBank Gene Database

M55602

GenBank Protein Database

177960

UniProtKB

P19801

UniProt Accession

AOC1_HUMAN

UniProtKB

Q9TRC7

UniProt Accession

AOC1_PIG

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10966

GeneCards

SLC22A2

GenBank Gene Database

X98333

GenBank Protein Database

2281942

Guide to Pharmacology

1020

UniProtKB

O15244

UniProt Accession

S22A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10968

GenAtlas

SLC22A4

GeneCards

SLC22A4

GenBank Gene Database

AB007448

GenBank Protein Database

2605501

UniProtKB

Q9H015

UniProt Accession

S22A4_HUMAN

International reference pricing

4 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.28/tablet

To $5.60/g

Apo-Amiloride 5 mg Tablet

$0.28/tablet

Midamor 5 mg tablet

$1.19/tablet

Amiloride hcl 5 mg tablet

$1.49/tablet

Amiloride hcl powder

$5.60/g

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated about 1 month ago(4 Mar 2026)

Back to medicines

Amiloride 500micrograms/5ml oral solution

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
13

Chemical identifiers

Amiloride

Additional database identifiers

International reference pricing

DrugBank citations

Amiloride 500micrograms/5ml oral solution

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science13

Chemical identifiers

Amiloride

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
13